Muls, Ann http://orcid.org/0000-0002-7678-859X
Taylor, Alexandra
Lalondrelle, Susan
Kabir, Mohammed
Norton, Christine
Hart, Ailsa
Andreyev, H. Jervoise
Funding for this research was provided by:
National Institute for Health Research (CDRF-2014-05-004)
Article History
Received: 8 October 2019
Accepted: 14 January 2020
First Online: 29 January 2020
Compliance with ethical standards
:
: Ms. Muls reports grants from the National Institute for Health Research, during the conduct of the study. Dr. Taylor has nothing to disclose. Dr. Lalondrelle reports personal fees from Sanofi Genzyme, grants from MSD, personal fees from Roche, grants and personal fees from Elekta, outside the submitted work. Mr. Mohammed has nothing to disclose. Professor Norton reports personal fees from Takeda, personal fees from Tillotts Pharma, personal fees from Ferring, outside the submitted work. Professor Hart has served as a consultant, advisory board member or speaker for AbbVie, Atlantic, Bristol-Myers Squibb, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda. She also serves on the Global Steering Committee for Genentech. Professor Andreyev reports non-financial support from GE Healthcare and manufacturers of SeHCAT, outside the submitted work.The corresponding author has full control over the primary data.
: The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.